The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company ...

Britain's Terry Smith made public for the first time on Thursday why his fund dumped its Diageo stake last year, citing ...